MLLT11-TRIL complex promotes the progression of endometrial cancer through PI3K/AKT/mTOR signaling pathway

Area of Science:

• Gynecologic Oncology
• Molecular Biology
• Bioinformatics

Background:

• Endometrial cancer (EC) is a prevalent gynecological malignancy with complex regulatory mechanisms.
• Current single-molecule therapies for EC exhibit limited efficacy due to resistance and side effects.
• Identifying novel molecular targets is crucial for developing more effective EC treatments.

Purpose of the Study:

• To identify key regulatory molecules in endometrial cancer (EC) through integrated bioinformatics and experimental approaches.
• To elucidate the molecular mechanisms underlying EC progression.
• To explore novel therapeutic targets for EC treatment.

Main Methods:

• Bioinformatics analysis to identify potential candidate molecules in EC.
• In vivo and in vitro experimental validation of identified molecules.
• Molecular dynamics simulations to detail intermolecular interactions.
• Analysis of the PI3K/AKT/mTOR signaling pathway.

Main Results:

• MLLT11 and TRIL were identified as significant regulatory molecules in EC.
• A novel heteromultimer complex, MLLT11-TRIL, was discovered.
• This complex acts as an agonist for AKT protein, inducing phosphorylation at threonine 308.
• The MLLT11-TRIL complex activates the PI3K/AKT/mTOR signaling pathway, crucial in tumor progression.

Conclusions:

• The MLLT11-TRIL complex is a novel activator of the PI3K/AKT/mTOR pathway in EC.
• Simultaneous targeting of MLLT11 and TRIL, or disruption of their complex formation, can inhibit EC progression.
• This study presents a new therapeutic strategy for endometrial cancer by targeting the MLLT11-TRIL complex.